News

Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm

Zurich-Schlieren, June 15, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the company will present updated preliminary results from the ongoing Phase 2 study of its lead proprietary oncology drug MP0250 at the 23th Annual...

read more

InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models

Schlieren, Switzerland – June 13, 2018 InSphero AG today announced that it has raised USD 10 million in its latest funding round with additional financing, secured from internal and external investors, bringing its total funding to date to USD 35 million. An innovative provider of 3D cellbased platforms for drug discovery and efficacy...

read more

Kuros Biosciences announces start of of randomized controlled trial of MagnetOs in spinal fusion

Study should further enhance competitive positioning of MagnetOs Kuros announced that the University Medical Center Utrecht (UMCU) in the Netherlands has obtained approval from its ethical committee to start an investigator-led multicenter study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The study is entitled "A Randomized Controlled Trial of MagnetOs®...

read more